Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (AP-HP)
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
This investigational cell therapy consists of autologous bone marrow-derived mesenchymal stem cells (MSCs) developed by Assistance Publique - Hôpitaux de Paris (AP-HP). It is specifically designed for the treatment of cardiac allograft vasculopathy (CAV) in heart transplant recipients. The therapy involves the extraction of the patient's own bone marrow, from which MSCs are isolated and expanded. The final product, a cell suspension containing approximately 40 million MSCs per ml, is delivered via intramyocardial injection guided by the NOGA cardiac mapping system. The mechanism of action is based on the regenerative and immunomodulatory properties of MSCs, which are intended to improve myocardial perfusion, promote angiogenesis, and mitigate the chronic inflammatory processes that drive coronary vasculopathy in the transplanted heart.
- Other names
- autologous mesenchymal stem cellsbone marrow-derived mesenchymal stem cellsMSC therapy (AP-HP)
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (AP-HP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (AP-HP).